BTEB3 Inhibitors
BTEB3 inhibitors are a class of chemical compounds designed to specifically target and modulate the activity of the BTEB3 protein, a transcription factor belonging to the Krüppel-like factor (KLF) family. BTEB3, also known as KLF8, plays a crucial role in regulating gene expression related to cell proliferation, differentiation, and various cellular processes. By binding to BTEB3, these inhibitors interfere with its ability to bind DNA at specific promoter regions, thereby altering the transcription of downstream genes. This modulation can lead to significant changes in cellular functions governed by the genes under BTEB3 control.
The chemical structures of BTEB3 inhibitors are typically characterized by functional groups that enable high-affinity interactions with the DNA-binding domains of the BTEB3 protein. Many of these compounds are designed to interact with the zinc finger motifs of BTEB3, which are essential for its binding to DNA. By targeting these motifs, the inhibitors effectively prevent BTEB3 from recognizing and binding to its specific DNA sequences. The development of BTEB3 inhibitors often involves techniques such as high-throughput screening and structure-based drug design to identify molecules with optimal binding characteristics. Understanding the three-dimensional structure of BTEB3 and its interaction with DNA is critical in this process, as it allows for the rational design of inhibitors that can achieve specificity and potency by precisely fitting into the active sites or altering the protein's conformation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide may downregulate BTEB3 by disrupting the formation of transcription initiation complexes, thereby reducing RNA polymerase II-mediated transcription of the BTEB3 gene. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D could decrease BTEB3 synthesis by binding to DNA at transcription initiation complexes, obstructing the transcriptional journey of RNA polymerase along the DNA, and thereby preventing BTEB3 mRNA elongation. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin specifically targets RNA polymerase II, which transcribes the BTEB3 gene; this toxin would reduce BTEB3 expression by blocking the polymerase's ability to produce mRNA transcripts. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin could inhibit BTEB3 expression by stabilizing the covalent DNA-topoisomerase I complex during transcription, interrupting DNA replication processes and potentially leading to a decrease in BTEB3 mRNA synthesis. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A can selectively bind to G-C rich regions of DNA, including promoters of certain genes like BTEB3, reducing transcriptional initiation and leading to decreased BTEB3 mRNA levels. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine inhibits the Hedgehog signaling pathway; if BTEB3 expression is under the control of this pathway, cyclopamine could result in the downregulation of BTEB3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin suppresses mTOR activity, which is crucial for cell growth and protein synthesis; this suppression could lead to a decrease in the global protein synthesis machinery, potentially reducing BTEB3 protein levels. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90, a chaperone involved in the correct folding of many proteins; inhibition of Hsp90 can lead to a targeted reduction in the stability and function of client proteins, potentially including BTEB3. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases that are necessary for the phosphorylation of the carboxy-terminal domain of RNA polymerase II, which is a critical step for BTEB3 transcription; this could result in reduced BTEB3 expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 directly inhibits the activity of BET bromodomain proteins that are important for chromatin remodeling and control of gene expression, which could lead to decreased transcription of BTEB3. | ||||||